PCYC Completes RESONATE Enrollment Zacks.com ... which is being conducted to evaluate ibrutinib in mantle cell lymphoma (MCL) patients whose disease has progressed even after having received Velcade (bortezomib) therapy and at least one prior Rituxan (rituximab)-containing chemotherapy regimen. |
